找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Cervical Cancer; Jaime G. de la Garza-Salazar,Flavia Morales-Vásque Book 2017 Springer International Publishing Switzerland 2017 cervical

[復(fù)制鏈接]
樓主: PLY
41#
發(fā)表于 2025-3-28 18:03:43 | 只看該作者
42#
發(fā)表于 2025-3-28 20:33:18 | 只看該作者
43#
發(fā)表于 2025-3-29 00:38:28 | 只看該作者
Cervical Cancer Cytology and Pathology,al/vaginal cytology, including recommendations for a proper cytologic report. Furthermore, the main cytologic criteria used in the diagnosis of squamous and glandular invasive cervical neoplasia precursor lesions are included. In the final part of the cytology section, some advantages and drawbacks
44#
發(fā)表于 2025-3-29 05:27:32 | 只看該作者
45#
發(fā)表于 2025-3-29 10:22:37 | 只看該作者
Imaging in Cervical Cancer,tion of Gynecology and Obstetrics (FIGO) criteria, cancer staging systems have been shown to be deficient for the examination of prognostic factors of CC, including tumor size and infiltration of the parametria or pelvic wall, as well as for the evaluation of nodal metastases. In this regard, imagin
46#
發(fā)表于 2025-3-29 11:55:42 | 只看該作者
47#
發(fā)表于 2025-3-29 18:10:22 | 只看該作者
Surgical Treatment for Advanced or Recurrent Disease in Cervical Cancer,nding on the survival disease-free, the site and size of recurrence can be set 5-year survivals of 48–60%. Since it was first reported in 1948, pelvic exenteration has been used in the treatment of advanced pelvic cancers. The original procedure has been modified in an attempt to preserve urinary or
48#
發(fā)表于 2025-3-29 21:19:26 | 只看該作者
49#
發(fā)表于 2025-3-30 00:32:03 | 只看該作者
50#
發(fā)表于 2025-3-30 04:02:04 | 只看該作者
Immuno-Oncology in Cervical Cancer,une-mediated treatments, or immuno-oncology, currently represent 6% of cancer therapies, and in the next 10 years, this percentage is expected to increase up to 70%. There are ongoing efforts to develop specific immunotherapies, such as immunomodulatory drugs and antibodies, to treat CC in combinati
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 12:36
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
宜都市| 田林县| 攀枝花市| 莱西市| 大同县| 清流县| 库车县| 江西省| 师宗县| 屯留县| 凭祥市| 房山区| 郎溪县| 五大连池市| 陆河县| 黄浦区| 洛扎县| 肥东县| 灵山县| 介休市| 望奎县| 惠东县| 玉溪市| 芷江| 林州市| 凤庆县| 赞皇县| 法库县| 那曲县| 昂仁县| 闻喜县| 皮山县| 九江县| 疏附县| 巧家县| 巫溪县| 文山县| 和田县| 云阳县| 白城市| 双鸭山市|